02:31 PM EDT, 07/22/2024 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Monday it repriced the roughly $2.7 billion outstanding balance of its term loan facility, which is expected to yield annual interest savings of about $23 million.

The repricing reduced the applicable margin above the term secured overnight financing rate by 75 basis points 225 basis points and removed the credit spread adjustment, the company said.

The company's Jazz Investments unit, meanwhile, has decided that its 2.000% exchangeable senior notes due 2026 will be settled with a combination of cash and ordinary shares of Jazz Pharmaceuticals ( JAZZ ), it said.

Price: 109.29, Change: +0.28, Percent Change: +0.26